AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01632462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VSL#3
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks.
Study NCT02613962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy or surgical resection of tumor and blood sampling
Study NCT01480336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone Plus Ranolazine
Description: Ranolazine 500mg by mouth twice daily
Study NCT01480336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amiodarone with Placebo
Description: stabel dose of amiodarone as prescribed by cardiologist
Study NCT04133467 — intervention group
Intervention type: OTHER
Intervention: scalp block
Description: intravenous acetaminophen according to the body weight, plus intravenous tramadol 1 mg/kg)
Study NCT04141384 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Modular Interactive Tiles System, MITS
Description: The modular robotic brick system was developed by Danish scholar Prof. Henrik Hautop Lund in collaboration with the University of Siena in Italy to develop a new tool. The system uses the design principles of different levels of daily life activities, combined with the way of cognitive games, Lego toys can combine different game concepts, with a set of individual or multi-person activity programs with hands or feet, provide a set Modular floor tiles for stroke patients and the elderly.
Study NCT00978211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOTA-TOC Treatment
Description: Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of~* renal toxicity~* loss of patient transferability or~* denial of further treatment.
Study NCT01473082 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFNA Augmentation (Synthes)
Description: Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)
Study NCT01473082 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFNA (Synthes)
Description: Proximal Femoral Nail Antirotation (PFNA)
Study NCT02488369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET / CT
Study NCT00718783 — intervention group
Intervention type: OTHER
Intervention: Tissue samples taken from retinoblastoma
Description: Tissue banking
Study NCT00718783 — intervention group
Intervention type: OTHER
Intervention: 5 ml peripheral blood
Description: White blood cells will be isolated from the blood sample as a source of genomic DNA.
Study NCT01425008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN2480
Description: Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
Study NCT02097914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational print materials and coaching call
Description: Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
Study NCT00333359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP13512 (GEn)
Description: 1200 mg XP13512, orally, once daily for 52 weeks
Study NCT03927274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Intratumorally-administered topotecan using convection-enhanced delivery (CED) in patients with suspected recurrent/progressive High Grade Glioma (HGG) requiring stereotactic biopsy and is focused on investigating topotecan brain tissue distribution and determining the safety, toxicity, and tolerability of intratumorally-administered topotecan.
Study NCT04368728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b1
Description: Intramuscular injection
Study NCT04368728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: Intramuscular injection
Study NCT04368728 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: BNT162b2
Description: Intramuscular injection
Study NCT04368728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT04368728 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2SA
Description: Intramuscular injection
Study NCT02148965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise / Physical Activity
Description: Lifestyle intervention Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
Study NCT04451421 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change of standing Angle
Description: Change the patient's standing Angle by using an electric bed
Study NCT02922374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
Study NCT04086394 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pectoral Nerve Block
Description: Patients who were given 20 cc of 0.25% Marcaine as part of the pectoralis nerve block
Study NCT04086394 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Surgery without Nerve Block
Description: Patient's underwent indicated procedure without regional pectoralis nerve block
Study NCT00520884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin Infusion - Healthy
Description: At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
Study NCT00520884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin Infusion - Frail
Description: At time 0, a graded infusion of Ghrelin of 2.5, 5.0, and 10.0 pmol/kg/min will be infused in one of the IV sites for 60 minutes each, totalling 180 minutes when the infusion will be stopped.
Study NCT00520884 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion -Healthy
Description: At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
Study NCT00520884 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion - Frail
Description: At time 0, an infusion of saline will be started in one of the IV sites (an equivalent amount to compare to the Ghrelin infusion) and will be infused in a stepwise fashion continued until 180 minutes, when the infusion will be stopped.
Study NCT03284671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bifocal stimulation with tDCS
Description: Patients will receive an active Treatment with tDCS (10 sessions of 30 mn with an intensity of 2 mA)
Study NCT04481984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Hand exercise
Description: Isometric exercise; patients squeezed a hand exercise ball for 60 seconds. This exercise repeated 15-times/3 set per day.~Stretching exercises; self-administered stretching exercises were as follows; i) forearm supination and pronation, ii) wrist flexion and extension, iii) finger flexion, extension, and abduction iv) thumb flexion, extension, and abduction. These exercises repeated 10-times/2 set per day.
Study NCT04481984 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care advice
Description: Patients received care advice including avoiding cold exposure and trauma.
Study NCT02998775 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Plasma Sampling
Description: No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
Study NCT01745250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Lips
Description: Lip treatment of both upper and lower lip
Study NCT01745250 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvederm Ultra Smile
Description: Lip treatment of both upper and lower lip
Study NCT03852251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 by intravenous administration.
Study NCT03852251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
Study NCT03852251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Subjects will receive AK104 in combination with oxaliplatin and capecitabine.
Study NCT03217006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single arterial graft
Description: This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
Study NCT03217006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple arterial grafting
Description: This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
Study NCT02833974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2245035 Nasal Spray Solution
Description: GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
Study NCT02833974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray Solution
Description: Nasal Spray Solution as for GSK2245035 without active ingredient.
Study NCT04289337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combined probiotics (1)
Description: Subjects used one oral combined probiotics (1) tablet each morning, noon, and evening for 4 weeks.
Study NCT04289337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combined probiotics (2)
Description: Subjects used one oral combined probiotics (2) tablet each morning, noon, and evening for 4 weeks.
Study NCT04289337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combined heat-killed probiotics (1)
Description: Subjects used one oral combined heat-killed probiotics (1) tablet each morning, noon, and evening for 4 weeks.
Study NCT04289337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combined heat-killed probiotics (2)
Description: Subjects used one oral combined heat-killed probiotics (2) tablet each morning, noon, and evening for 4 weeks.
Study NCT04289337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic metabolites
Description: Subjects used one oral probiotic metabolites tablet each morning, noon, and evening for 4 weeks.
Study NCT04289337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects used one oral placebo tablet each morning, noon, and evening for 4 weeks.
Study NCT02232802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium
Description: comparison of bioavailability of generic Enoxaparin Sodium and Clexane
Study NCT01579188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GV1001
Description: Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
Study NCT01579188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: two injections of normal saline injected in the same manner as the experimental drug, GV1001
Study NCT03902509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: pirfenidone capsule made in China
Study NCT03902509 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: basic treatment
Description: glucocorticoid and expectant treatment etc.
Study NCT03902509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basic treatment
Description: glucocorticoid and expectant treatment etc.
Study NCT01556607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDT-637
Description: Inhaled doses of MDT-637 over a 24 hour period at 3 visits
Study NCT01556607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03600779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inhomogeneous Magnetisation Transfer (ihMT) sequence
Description: robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T
Study NCT03600779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inhomogeneous Magnetisation Transfer (ihMT) sequence
Description: robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 1.5T
Study NCT03600779 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T
Description: robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
Study NCT03600779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T
Description: robust technique has shown great sensitivity for evaluating the demyelination processes using MRI at 3T
Study NCT00457015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ecallantide
Description: dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
Study NCT00457015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffer Saline (PBS), pH 7.0
Description: given as three 1mL subcutaneous injections.
Study NCT00466466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
Study NCT00075023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide Gel
Study NCT00075023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Gel
Study NCT04503954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic disease self-management program
Description: The chronic disease self-management program is based on the self-efficacy theory for improving health behavior, by the solve health problem skill, health life style, emotion management skill, improve intention of health condition in people with chronic disease.
Study NCT04503954 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General psychiatric intervention
Description: General psychiatric intervention contains the activities in psychiatric center.
Study NCT03471702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart External Drain - SED
Description: Aqueduct's Smart External Drain (SED) is a gravity based system which utilizes a proprietary reference shroud which eliminates the need for manual adjustment of the system in the external management of CSF drainage.
Study NCT01243710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taurolidine with heparin (500 units/ ml)
Description: Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
Study NCT01243710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolidine with heparin (500 units/ ml)
Description: Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
Study NCT00842426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management program (SM)
Description: Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.~During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management.
Study NCT00842426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care management program (CM)
Description: In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.~During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support.
Study NCT02443363 — intervention group
Intervention type: OTHER
Intervention: Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,
Study NCT02443363 — intervention group
Intervention type: DEVICE
Intervention: Tanita BC 418- Bioelectrical impedance analysis
Description: The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
Study NCT01833637 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APN Intervention
Description: Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
Study NCT04100252 — intervention group
Intervention type: OTHER
Intervention: AFI via transabdominal ultrasonography
Description: AFI via transabdominal ultrasonography was performed at the time of diagnosis.
Study NCT00131248 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metaclopramide
Study NCT03321136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: 0.025 mg LSD per os, single dose
Study NCT03321136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: 0.05 mg LSD per os, single dose
Study NCT03321136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: 0.1 mg LSD per os, single dose
Study NCT03321136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: 0.2 mg LSD per os, single dose
Study NCT03321136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LSD
Description: 0.2 mg LSD plus 40 mg ketanserin per os, single doses each
Study NCT03321136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing mannitol looking identical to the other drugs.
Study NCT01018433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T-SIB
Description: Treatment for self-injurious behaviors; study psychotherapy
Study NCT01018433 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Can include other psychotherapy and pharmacotherapy